Signature Diagnostics to Use Affymetrix Microarray Technology for Advanced Colorectal Cancer Tests

Affymetrix, Inc. (NASDAQ:AFFX) and Signature Diagnostics AG (Signature Dx) today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix(R) microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.

Source: Affymetrix